METTL14在初诊急性髓系白血病患者中的表达及其临床意义  

The Expression of METTL14 in Patients with Newly Diagnosed Acute Myeloid Leukemia and Its Clinical Significance

作　　者：李佳佳[1] 伍燕平 张孟孟 王蒙 张平平 刘林[1] LI Jia-Jia;WU Yan-Ping;ZHANG Meng-Meng;WANG Meng;ZHANG Ping-Ping;LIU Lin(Department of Hematology,The First Affiliated Hospital of Bengbu Medical College,Bengbu 233003,Anhui Province,China)

机构地区：[1]蚌埠医学院第一附属医院血液科,安徽蚌埠233003

出　　处：《中国实验血液学杂志》2024年第2期376-381,共6页Journal of Experimental Hematology

基　　金：安徽省自然科学基金青年项目(2108085QH324);安徽省卫生健康科研重点项目(AHWJ2023A10059)。

摘　　要：目的:通过检测RNA甲基转移酶样14(METTL14)在初诊急性髓系白血病(AML)患者骨髓中的表达水平,探讨METTL14表达在初诊AML患者中的临床与预后意义。方法:收集100例初诊AML患者骨髓标本作为AML组,60例缺铁性贫血(IDA)患者骨髓标本作为对照组,并收集AML患者的临床资料。采用实时荧光定量PCR(qRT-PCR)检测METTL14在两组患者骨髓中的表达水平,并分析AML患者的METTL14表达水平高低与其临床病理特征及预后的关系。采用Kaplan-Meier曲线分析METTL14对AML患者总体生存时间(OS)的影响。通过Cox风险回归模型分析影响AML患者的预后因素。结果:与对照组相比,METTL14在AML患者中表达明显升高(P<0.05)。与低表达组比较,METTL14高表达组患者表现出高龄、高骨髓细胞数、疗效差及预后不良,差异具有统计学意义(P<0.05)。METTL14高表达组的OS较低表达组显著缩短(P<0.05)。METTL14高表达是影响AML预后的独立危险因素。结论:METTL14在AML患者中明显高表达,与较差的临床病理特征及不良预后相关,可作为判断AML患者预后的指标和潜在的治疗靶点。Objective:To detect the expression of RNA methyltransferase 14(METTL14)in bone marrow of patients with newly diagnosed acute myeloid leukemia(AML),and to investigate the clinical and prognostic significance of METTL14 expression in newly diagnosed AML.Methods:Bone marrow samples were collected from 100 patients with newly diagnosed AML as observation group and 60 patients with iron deficiency anemia AML as control group.And collected the clinical data of the AML patients.Real-time quantitative PCR(qRT-PCR)was used to detect the expression level of METTL14 in AML and IDA patients.The relationship between the expression level of METTL14 and clinicopathological features,prognosis was analyzed.Kaplan-Meier curves were used to analyze the effect of METTL14 on overall survival(OS)in AML patients.Cox risk regression model was used to analyze the prognostic factors affecting in patients with AML.Results:Compared with the control group,the expression of METTL14 was significantly increased in AML patients(P<0.05).Compared with the METTL14 low-expression group,patients in the METTL14 high-expression group had advanced age,high bone marrow cell number,poor efficacyand poor prognosis(P<0.05).The overall survival time of patients with the METTL14 high-expression group was significantly shorter than that of the low-expression group(P<0.05).The high expression of METTL14 was an independent risk factor for poor prognosis in AML.Conclusion:METTL14 is significantly overexpressed in AML patients,and its correlated with poor clinicopathological features and poor prognosis.It can be used as a prognostic marker and potential therapeutie target for AML patients.

关 键 词：急性髓系白血病 RNA甲基转移酶样14 临床意义 预后 

分 类 号：R733.71[医药卫生—肿瘤]